Leaked Data Boost J&J and Legend’s CAR-T Carvykti But Manufacturing Issues Remain
Risk Of Progression Or Death Cut By 74%
An accidental peek at data suggests Carvykti can outperform Bristol Myers Squibb’s rival CAR-T therapy Abecma, if it can prove a survival benefit and overcome manufacturing limitations that are hampering both products.
